{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
levobunolol
to a specific field?
There is one exact (name or code) match for levobunolol
Status:
US Approved Rx
(1994)
Source:
ANDA074326
(1994)
Source URL:
First approved in 1985
Source:
NDA019219
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Levobunolol, sold under the brand name Betagan, has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Levobunolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure cardiogenic shock; or hypersensitivity to any component of these products.
Showing 1 - 9 of 9 results
Status:
US Approved Rx
(1994)
Source:
ANDA074326
(1994)
Source URL:
First approved in 1985
Source:
NDA019219
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Levobunolol, sold under the brand name Betagan, has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Levobunolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure cardiogenic shock; or hypersensitivity to any component of these products.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Bunolol is non-selective beta-adrenoreceptor antagonist with significant antihypertensive, antiarrhythmic and local anesthetic activities. Bunolol is a racemic mixture and Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity. Bunolol is 3 times as potent as propranolol by i.v. administration in anesthetized dogs in antagonizing the cardiovascular actions of isoproterenol and the response to cardioaccelerans nerve stimulation. When oral doses were given to unanesthetized dogs with subsequent induction of anesthesia, Bunolol was 20 times as potent as propranolol. The β-adrenergic blocking activity of Bunolol appeared to be competitive, and the activity was largely restricted to the l-isomer. Bunolol is extensively metabolized by both oxidative and reductive routes.
Status:
Investigational
Source:
NCT03654508: Not Applicable Interventional Completed Asthma in Children
(2018)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1994)
Source:
ANDA074326
(1994)
Source URL:
First approved in 1985
Source:
NDA019219
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Levobunolol, sold under the brand name Betagan, has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Levobunolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure cardiogenic shock; or hypersensitivity to any component of these products.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Bunolol is non-selective beta-adrenoreceptor antagonist with significant antihypertensive, antiarrhythmic and local anesthetic activities. Bunolol is a racemic mixture and Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity. Bunolol is 3 times as potent as propranolol by i.v. administration in anesthetized dogs in antagonizing the cardiovascular actions of isoproterenol and the response to cardioaccelerans nerve stimulation. When oral doses were given to unanesthetized dogs with subsequent induction of anesthesia, Bunolol was 20 times as potent as propranolol. The β-adrenergic blocking activity of Bunolol appeared to be competitive, and the activity was largely restricted to the l-isomer. Bunolol is extensively metabolized by both oxidative and reductive routes.
